EU DRUG SECTOR RESEARCH REPORT Published COMPETITION-2008: FRONT drug is

Preliminary report on competition in the sector araşitırması European Komisyonuilaç published. Not according to the report, such as competition in the sector. Especially for large companies to market drugs jenrik to avoid or to delay. Examples in the report between the years 2000-2007 in the 17 member countries over protection panet received the drugs. If the original company before tarafınadn generic 3 billion pound savings were not, or if geciktilmemiş can be calculated. Report on the patent strategy of firms conducting aggressive efforts to prevent the first describes the generic.
One of the most widely used method in the treacherous beam receiving patent (patent clustering). 1300 for a drug that a company can receive a separate patent. Other methods with the generic drug companies on every pretext to prosecute. Though 60% of cases for generic drug manufacturers to earn more than the average of the 3-year isede each case is considered better for the size of the emerging business.
We hope that at least the members of the national drug sanayiimizin valuable time to read the attached report and develop strategies accordingly. Em, as so far at this time that you "manually from the wedding feast" philosophy will wait until the egg comes to the door and then as always, will ağlaş ..


DRUG biggest rebellion

Revolt of the European Commission. Issues related to "drug report" issued the Commission, a big drug companies, cheap drugs to prevent entry into the European Union said. Therefore, loss of 3 billion euro tasaruf health sector. Rebellion of the European Commission, the EU countries access to cheap medicines to kolaylaştırısa, it is expected to make use of Turkey.

The report from the Commission, the big companies between the years 2000-2007 of this attitude of the community health services that can be done to save a loss of 3 billion that has explained why.

Commission to market the drug companies to prevent competitors in the legal initiatives that were added.

Pharmaceutical companies take measures in accordance with law, emphasized the development and research objectives is to protect the investment says.

European market entry of generic drug must

After the patent expired drugs for pharmaceutical companies producing cheaper versions of products into the European market are having trouble for a long time was expressed.

European Commission, the pharmaceutical manufacturers to enter the European market sometimes drugs cheaper to prevent a lot of overlap, have made application.

Commission at a time for a single drug, a full application for a patent in 1300 was done to this example.

700 cases

The European Commission's report, indicated that similar problems are experienced at the national level.

Approximately 700 patents related to open cases in the report that more than 200 brand name pharmaceutical companies in the main drug producing company to reach agreement was announced between.

More than 10 per cent of this agreement, the drug blocked the entrance to the market.

Global ilç printing sector

Unfair practices of the European Commission found that large penalties if drug companies could not be saved.

The Commission's report, has increased the pressure on the global pharmaceutical industry.

January 20 in the U.S. is prepared to take over the tasks of the new president Barack Obama'nın, the country is expected to work to reduce drug costs.